FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986892074> ?p ?o ?g. }

• W1986892074 endingPage "e295" @default.
• W1986892074 startingPage "e285" @default.
• W1986892074 abstract "Background The use of sunitinib at conventional doses (50 mg/d, 6-week cycles: 4 weeks of treatment, then 2 weeks of no treatment) in Asian patients with metastatic renal cell carcinoma (mRCC) is associated with high real-world toxicities. Patients and Methods Patients with mRCC treated with sunitinib between 2005 and 2012 at 4 centers representing a near-national cohort (n = 160) in Singapore were evaluated. One hundred twenty-seven consecutive patients in 1 center were treated with a novel attenuated-dose sunitinib regimen (37.5 mg/d, 6-week cycle: 4 weeks of treatment, then 2 weeks of no treatment) with outcomes captured in a prospective registry. Efficacy and safety outcomes of these patients were compared against those who received sunitinib at conventional dosing (n = 33) at all 4 centers. Statistical modeling was adjusted for baseline prognostic criteria and therapy line where possible. Results Overall survival from treatment initiation (OSinitiation), overall survival from the first documented metastasis (OStotal), and progression-free survival (PFS) were similar for patients who received first-line sunitinib for conventional relative to attenuated dose regimens (OSinitiation: 18.3 vs. 16.5 months, respectively; P = .54; OStotal: 27.4 vs. 21.8 months, respectively; P = .45; PFS: 6.7 vs. 7.9 months, respectively; P = .64), similar to real-world outcomes in Western studies. A marked lower rate of severe toxicities, dose delays, and reductions were observed with the attenuated dose regimen, with 75/127 (59%), rather than 28/33 (85%) for the conventional dose arm who experienced Grade ≥ 3 toxicities (P = .0088); 31/127 (24%) rather than 19/33 (58%) who experienced dose delays (P = .0004); and 44/127 (35%) rather than 23/33 (70%) who experienced dose reduction (P = .0005) during their course of treatment. Conclusion An attenuated dose regimen of sunitinib yielded comparable real-world efficacy outcomes, with considerable reduction in toxicities as documented in a prospective registry." @default.
• W1986892074 created "2016-06-24" @default.
• W1986892074 creator A5007311021 @default.
• W1986892074 creator A5009132120 @default.
• W1986892074 creator A5014643846 @default.
• W1986892074 creator A5024708104 @default.
• W1986892074 creator A5031524039 @default.
• W1986892074 creator A5039048707 @default.
• W1986892074 creator A5040482537 @default.
• W1986892074 creator A5043046640 @default.
• W1986892074 creator A5051368035 @default.
• W1986892074 creator A5060981830 @default.
• W1986892074 creator A5068401391 @default.
• W1986892074 creator A5077867618 @default.
• W1986892074 creator A5079641556 @default.
• W1986892074 creator A5081294763 @default.
• W1986892074 date "2015-08-01" @default.
• W1986892074 modified "2023-09-26" @default.
• W1986892074 title "Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore" @default.
• W1986892074 cites W1953363591 @default.
• W1986892074 cites W1967487178 @default.
• W1986892074 cites W1973282535 @default.
• W1986892074 cites W2019607817 @default.
• W1986892074 cites W2033366833 @default.
• W1986892074 cites W2040143310 @default.
• W1986892074 cites W2044254728 @default.
• W1986892074 cites W2070407553 @default.
• W1986892074 cites W2097147116 @default.
• W1986892074 cites W2099088585 @default.
• W1986892074 cites W2103506609 @default.
• W1986892074 cites W2113788015 @default.
• W1986892074 cites W2116949558 @default.
• W1986892074 cites W2126958845 @default.
• W1986892074 cites W2139248078 @default.
• W1986892074 cites W2139511378 @default.
• W1986892074 cites W2143394625 @default.
• W1986892074 cites W2145046367 @default.
• W1986892074 cites W2146850908 @default.
• W1986892074 cites W2149456801 @default.
• W1986892074 cites W2149613039 @default.
• W1986892074 cites W2155319477 @default.
• W1986892074 cites W2160120519 @default.
• W1986892074 cites W2162424705 @default.
• W1986892074 cites W2171205120 @default.
• W1986892074 doi "https://doi.org/10.1016/j.clgc.2014.11.004" @default.
• W1986892074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25541325" @default.
• W1986892074 hasPublicationYear "2015" @default.
• W1986892074 type Work @default.
• W1986892074 sameAs 1986892074 @default.
• W1986892074 citedByCount "21" @default.
• W1986892074 countsByYear W19868920742014 @default.
• W1986892074 countsByYear W19868920742015 @default.
• W1986892074 countsByYear W19868920742016 @default.
• W1986892074 countsByYear W19868920742017 @default.
• W1986892074 countsByYear W19868920742018 @default.
• W1986892074 countsByYear W19868920742019 @default.
• W1986892074 countsByYear W19868920742020 @default.
• W1986892074 countsByYear W19868920742021 @default.
• W1986892074 countsByYear W19868920742023 @default.
• W1986892074 crossrefType "journal-article" @default.
• W1986892074 hasAuthorship W1986892074A5007311021 @default.
• W1986892074 hasAuthorship W1986892074A5009132120 @default.
• W1986892074 hasAuthorship W1986892074A5014643846 @default.
• W1986892074 hasAuthorship W1986892074A5024708104 @default.
• W1986892074 hasAuthorship W1986892074A5031524039 @default.
• W1986892074 hasAuthorship W1986892074A5039048707 @default.
• W1986892074 hasAuthorship W1986892074A5040482537 @default.
• W1986892074 hasAuthorship W1986892074A5043046640 @default.
• W1986892074 hasAuthorship W1986892074A5051368035 @default.
• W1986892074 hasAuthorship W1986892074A5060981830 @default.
• W1986892074 hasAuthorship W1986892074A5068401391 @default.
• W1986892074 hasAuthorship W1986892074A5077867618 @default.
• W1986892074 hasAuthorship W1986892074A5079641556 @default.
• W1986892074 hasAuthorship W1986892074A5081294763 @default.
• W1986892074 hasConcept C126322002 @default.
• W1986892074 hasConcept C126894567 @default.
• W1986892074 hasConcept C141071460 @default.
• W1986892074 hasConcept C143998085 @default.
• W1986892074 hasConcept C188816634 @default.
• W1986892074 hasConcept C2777288759 @default.
• W1986892074 hasConcept C2777472916 @default.
• W1986892074 hasConcept C2779490328 @default.
• W1986892074 hasConcept C2781413609 @default.
• W1986892074 hasConcept C71924100 @default.
• W1986892074 hasConceptScore W1986892074C126322002 @default.
• W1986892074 hasConceptScore W1986892074C126894567 @default.
• W1986892074 hasConceptScore W1986892074C141071460 @default.
• W1986892074 hasConceptScore W1986892074C143998085 @default.
• W1986892074 hasConceptScore W1986892074C188816634 @default.
• W1986892074 hasConceptScore W1986892074C2777288759 @default.
• W1986892074 hasConceptScore W1986892074C2777472916 @default.
• W1986892074 hasConceptScore W1986892074C2779490328 @default.
• W1986892074 hasConceptScore W1986892074C2781413609 @default.
• W1986892074 hasConceptScore W1986892074C71924100 @default.
• W1986892074 hasIssue "4" @default.
• W1986892074 hasLocation W19868920741 @default.
• W1986892074 hasLocation W19868920742 @default.
• W1986892074 hasOpenAccess W1986892074 @default.

• next